Previous close | 47.66 |
Open | 47.07 |
Bid | 47.63 x 1000 |
Ask | 47.66 x 900 |
Day's range | 47.05 - 47.92 |
52-week range | 34.98 - 48.87 |
Volume | |
Avg. volume | 6,566,070 |
Market cap | 67.82B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 112.74 |
EPS (TTM) | 0.42 |
Earnings date | 25 Apr 2023 - 01 May 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 52.76 |
Boston Scientific's (BSX) organic revenues at each of its core business segments and geographies increase in the fourth quarter of 2022.
Boston Scientific (BSX) delivered earnings and revenue surprises of -4.26% and 0.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical device companies' results are likely to reflect a sequential decline. Let's see how BSX, TMO, HOLX and ALGN fare this time.